Onco-hematology Molecular Testing Market (Blood Cancer Type: Chronic Myeloid Leukemia, Myeloproliferative Neoplasms, Acute Myeloid Leukemia, and Acute Lymphoblastic Leukemia) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Onco-hematology Molecular Testing Market (Blood Cancer Type: Chronic Myeloid Leukemia, Myeloproliferative Neoplasms, Acute Myeloid Leukemia, and Acute Lymphoblastic Leukemia) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031


Onco-hematology Molecular Testing Market – Scope of Report


TMR’s report on the global Onco-hematology Molecular Testing Market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global Onco-hematology Molecular Testing Market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Onco-hematology Molecular Testing Market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the Onco-hematology Molecular Testing Market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Onco-hematology Molecular Testing Market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Onco-hematology Molecular Testing Market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global Onco-hematology Molecular Testing Market.

The report delves into the competitive landscape of the global Onco-hematology Molecular Testing Market. Key players operating in the global Onco-hematology Molecular Testing Market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Onco-hematology Molecular Testing Market profiled in this report.

Key Questions Answered in Global Onco-hematology Molecular Testing Market Report
  • What is the sales/revenue generated by mobile photo printer across all regions during the forecast period?
  • What are the opportunities in the global Onco-hematology Molecular Testing Market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?
Onco-hematology Molecular Testing Market – Research Objectives and Research Approach

The comprehensive report on the global Onco-hematology Molecular Testing Market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Onco-hematology Molecular Testing Market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global Onco-hematology Molecular Testing .


1. Preface
  1.1. Market Definition and Scope
  1.2. Market Segmentation
  1.3. Key Research Objectives
  1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Onco-hematology Molecular Testing Market
4. Market Overview
  4.1. Introduction
4.1.1. Segment Definition
  4.2. Overview
  4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
  4.4. Global Onco-hematology Molecular Testing Market Analysis and Forecast, 2017-2031
5. Key Insights
  5.1. Overview of Onco-hematology Molecular Testing Market
  5.2. Key Product/ Brand Analysis
  5.3. Pipeline Analysis
  5.4. COVID-19 Pandemic Impact on Industry
6. Global Onco-hematology Molecular Testing Market Analysis and Forecast, by Blood Cancer Type
  6.1. Introduction & Definition
  6.2. Key Findings/Developments
  6.3. Market Value Forecast, by Blood Cancer Type, 2017-2031
6.3.1. Chronic Myeloid Leukemia
6.3.1.1. Polycythemia Vera
6.3.1.2. Essential Thrombocythaemia
6.3.1.3. Myelofibrosis
6.3.2. Myeloproliferative Neoplasms
6.3.3. Acute Myeloid Leukemia
6.3.4. Acute Lymphoblastic Leukemia
  6.4. Market Attractiveness Analysis, by Blood Cancer Type
7. Global Onco-hematology Molecular Testing Market Analysis and Forecast, by Blood Cancer Biomarker
  7.1. Introduction & Definition
  7.2. Key Findings/Developments
  7.3. Market Value Forecast, by Blood Cancer Biomarker, 2017-2031
7.3.1. BCR-ABL1 MBCR
7.3.2. JAK2
7.3.3. CALR
7.3.4. MPL
7.3.5. PML-RARA
7.3.6. NPM1
7.3.7. RUNX1-RUNX1T1
7.3.8. CBFB-MYH11
7.3.9. BCR-ABL1 mbcr
  7.4. Market Attractiveness Analysis, by Blood Cancer Biomarker
8. Global Onco-hematology Molecular Testing Market Analysis and Forecast, by Technology
  8.1. Introduction & Definition
  8.2. Key Findings/Developments
  8.3. Market Value Forecast, by Technology, 2017-2031
8.3.1. qPCR
8.3.2. dPCR
8.3.3. Next-Generation Sequencing
8.3.4. Others
  8.4. Market Attractiveness Analysis, by Technology
9. Global Onco-hematology Molecular Testing Market Analysis and Forecast, by End-user
  9.1. Introduction & Definition
  9.2. Key Findings/Developments
  9.3. Market Value Forecast, by End-user, 2017-2031
9.3.1. National Reference Lab/Specialty Lab
9.3.2. University Hospital/Oncology Center
9.3.3. Community Hospital/IDN (Regional/National
  9.4. Market Attractiveness Analysis, by End-user
10. Global Onco-hematology Molecular Testing Market Analysis and Forecast, by Region
  10.1. Key Findings
  10.2. Market Value Forecast, by Region, 2017-2031
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. Latin America
10.2.5. Middle East & Africa
  10.3. Market Attractiveness Analysis, by Region
11. North America Onco-hematology Molecular Testing Market Analysis and Forecast
  11.1. Introduction
11.1.1. Key Findings
  11.2. Market Value Forecast, by Blood Cancer Type, 2017-2031
11.2.1. Chronic Myeloid Leukemia
11.2.1.1. Polycythemia Vera
11.2.1.2. Essential Thrombocythaemia
11.2.1.3. Myelofibrosis
11.2.2. Myeloproliferative Neoplasms
11.2.3. Acute Myeloid Leukemia
11.2.4. Acute Lymphoblastic Leukemia
  11.3. Market Value Forecast, by Blood Cancer Biomarker, 2017-2031
11.3.1. BCR-ABL1 MBCR
11.3.2. JAK2
11.3.3. CALR
11.3.4. MPL
11.3.5. PML-RARA
11.3.6. NPM1
11.3.7. RUNX1-RUNX1T1
11.3.8. CBFB-MYH11
11.3.9. BCR-ABL1 mbcr
  11.4. Market Value Forecast, by Technology, 2017-2031
11.4.1. qPCR
11.4.2. dPCR
11.4.3. Next-Generation Sequencing
11.4.4. Others
  11.5. Market Value Forecast, by End-user, 2017-2031
11.5.1. National Reference Lab/Specialty Lab
11.5.2. University Hospital/Oncology Center
11.5.3. Community Hospital/IDN (Regional/National
  11.6. Market Value Forecast, by Country, 2017-2031
11.6.1. U.S.
11.6.2. Canada
  11.7. Market Attractiveness Analysis
11.7.1. By Blood Cancer Type
11.7.2. By Blood Cancer Biomarker
11.7.3. By Technology
11.7.4. By End-user
11.7.5. By Country
12. Europe Onco-hematology Molecular Testing Market Analysis and Forecast
  12.1. Introduction
12.1.1. Key Findings
  12.2. Market Value Forecast, by Blood Cancer Type, 2017-2031
12.2.1. Chronic Myeloid Leukemia
12.2.1.1. Polycythemia Vera
12.2.1.2. Essential Thrombocythaemia
12.2.1.3. Myelofibrosis
12.2.2. Myeloproliferative Neoplasms
12.2.3. Acute Myeloid Leukemia
12.2.4. Acute Lymphoblastic Leukemia
  12.3. Market Value Forecast, by Blood Cancer Biomarker, 2017-2031
12.3.1. BCR-ABL1 MBCR
12.3.2. JAK2
12.3.3. CALR
12.3.4. MPL
12.3.5. PML-RARA
12.3.6. NPM1
12.3.7. RUNX1-RUNX1T1
12.3.8. CBFB-MYH11
12.3.9. BCR-ABL1 mbcr
  12.4. Market Value Forecast, by Technology, 2017-2031
12.4.1. qPCR
12.4.2. dPCR
12.4.3. Next-Generation Sequencing
12.4.4. Others
  12.5. Market Value Forecast, by End-user, 2017-2031
12.5.1. National Reference Lab/Specialty Lab
12.5.2. University Hospital/Oncology Center
12.5.3. Community Hospital/IDN (Regional/National
  12.6. Market Value Forecast, by Country/Sub-region, 2017-2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
  12.7. Market Attractiveness Analysis
12.7.1. By Blood Cancer Type
12.7.2. By Blood Cancer Biomarker
12.7.3. By Technology
12.7.4. By End-user
12.7.5. By Country/Sub-region
13. Asia Pacific Onco-hematology Molecular Testing Market Analysis and Forecast
  13.1. Introduction
13.1.1. Key Findings
  13.2. Market Value Forecast, by Blood Cancer Type, 2017-2031
13.2.1. Chronic Myeloid Leukemia
13.2.1.1. Polycythemia Vera
13.2.1.2. Essential Thrombocythaemia
13.2.1.3. Myelofibrosis
13.2.2. Myeloproliferative Neoplasms
13.2.3. Acute Myeloid Leukemia
13.2.4. Acute Lymphoblastic Leukemia
  13.3. Market Value Forecast, by Blood Cancer Biomarker, 2017-2031
13.3.1. BCR-ABL1 MBCR
13.3.2. JAK2
13.3.3. CALR
13.3.4. MPL
13.3.5. PML-RARA
13.3.6. NPM1
13.3.7. RUNX1-RUNX1T1
13.3.8. CBFB-MYH11
13.3.9. BCR-ABL1 mbcr
  13.4. Market Value Forecast, by Technology, 2017-2031
13.4.1. qPCR
13.4.2. dPCR
13.4.3. Next-Generation Sequencing
13.4.4. Others
  13.5. Market Value Forecast, by End-user, 2017-2031
13.5.1. National Reference Lab/Specialty Lab
13.5.2. University Hospital/Oncology Center
13.5.3. Community Hospital/IDN (Regional/National
  13.6. Market Value Forecast, by Country/Sub-region, 2017-2031
13.6.1. China
13.6.2. Japan
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. Rest of Asia Pacific
  13.7. Market Attractiveness Analysis
13.7.1. By Blood Cancer Type
13.7.2. By Blood Cancer Biomarker
13.7.3. By Technology
13.7.4. By End-user
13.7.5. By Country/Sub-region
14. Latin America Onco-hematology Molecular Testing Market Analysis and Forecast
  14.1. Introduction
14.1.1. Key Findings
  14.2. Market Value Forecast, by Blood Cancer Type, 2017-2031
14.2.1. Chronic Myeloid Leukemia
14.2.1.1. Polycythemia Vera
14.2.1.2. Essential Thrombocythaemia
14.2.1.3. Myelofibrosis
14.2.2. Myeloproliferative Neoplasms
14.2.3. Acute Myeloid Leukemia
14.2.4. Acute Lymphoblastic Leukemia
  14.3. Market Value Forecast, by Blood Cancer Biomarker, 2017-2031
14.3.1. BCR-ABL1 MBCR
14.3.2. JAK2
14.3.3. CALR
14.3.4. MPL
14.3.5. PML-RARA
14.3.6. NPM1
14.3.7. RUNX1-RUNX1T1
14.3.8. CBFB-MYH11
14.3.9. BCR-ABL1 mbcr
  14.4. Market Value Forecast, by Technology, 2017-2031
14.4.1. qPCR
14.4.2. dPCR
14.4.3. Next-Generation Sequencing
14.4.4. Others
  14.5. Market Value Forecast, by End-user, 2017-2031
14.5.1. National Reference Lab/Specialty Lab
14.5.2. University Hospital/Oncology Center
14.5.3. Community Hospital/IDN (Regional/National
  14.6. Market Value Forecast, by Country/Sub-region, 2017-2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
  14.7. Market Attractiveness Analysis
14.7.1. By Blood Cancer Type
14.7.2. By Blood Cancer Biomarker
14.7.3. By Technology
14.7.4. By End-user
14.7.5. By Country/Sub-region
15. Middle East & Africa Onco-hematology Molecular Testing Market Analysis and Forecast
  15.1. Introduction
15.1.1. Key Findings
  15.2. Market Value Forecast, by Blood Cancer Type, 2017-2031
15.2.1. Chronic Myeloid Leukemia
15.2.1.1. Polycythemia Vera
15.2.1.2. Essential Thrombocythaemia
15.2.1.3. Myelofibrosis
15.2.2. Myeloproliferative Neoplasms
15.2.3. Acute Myeloid Leukemia
15.2.4. Acute Lymphoblastic Leukemia
  15.3. Market Value Forecast, by Blood Cancer Biomarker, 2017-2031
15.3.1. BCR-ABL1 MBCR
15.3.2. JAK2
15.3.3. CALR
15.3.4. MPL
15.3.5. PML-RARA
15.3.6. NPM1
15.3.7. RUNX1-RUNX1T1
15.3.8. CBFB-MYH11
15.3.9. BCR-ABL1 mbcr
  15.4. Market Value Forecast, by Technology, 2017-2031
15.4.1. qPCR
15.4.2. dPCR
15.4.3. Next-Generation Sequencing
15.4.4. Others
  15.5. Market Value Forecast, by End-user, 2017-2031
15.5.1. National Reference Lab/Specialty Lab
15.5.2. University Hospital/Oncology Center
15.5.3. Community Hospital/IDN (Regional/National
  15.6. Market Value Forecast, by Country/Sub-region, 2017-2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
  15.7. Market Attractiveness Analysis
15.7.1. By Blood Cancer Type
15.7.2. By Blood Cancer Biomarker
15.7.3. By Technology
15.7.4. By End-user
15.7.5. By Country/Sub-region
16. Competition Landscape
  16.1. Market Player - Competition Matrix (by tier and size of companies)
  16.2. Market Share Analysis, by Company, 2022
  16.3. Company Profiles
16.3.1. Asuragen, Inc.
16.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.1.2. Product Portfolio
16.3.1.3. Financial Overview
16.3.1.4. SWOT Analysis
16.3.1.5. Strategic Overview
16.3.2. Bio-Rad Laboratories, Inc.
16.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.2.2. Product Portfolio
16.3.2.3. Financial Overview
16.3.2.4. SWOT Analysis
16.3.2.5. Strategic Overview
16.3.3. ICON plc
16.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.3.2. Product Portfolio
16.3.3.3. Financial Overview
16.3.3.4. SWOT Analysis
16.3.3.5. Strategic Overview
16.3.4. Integrated DNA Technologies, Inc. (ArcherDx, Inc.)
16.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.4.2. Product Portfolio
16.3.4.3. Financial Overview
16.3.4.4. SWOT Analysis
16.3.4.5. Strategic Overview
16.3.5. Invivoscribe, Inc.
16.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.5.2. Product Portfolio
16.3.5.3. Financial Overview
16.3.5.4. SWOT Analysis
16.3.5.5. Strategic Overview
16.3.6. QIAGEN N.V.
16.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.6.2. Product Portfolio
16.3.6.3. Financial Overview
16.3.6.4. SWOT Analysis
16.3.6.5. Strategic Overview
16.3.7. Thermo Fisher Scientific, Inc.
16.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.7.2. Product Portfolio
16.3.7.3. Financial Overview
16.3.7.4. SWOT Analysis
16.3.7.5. Strategic Overview
16.3.8. Cepheid
16.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.8.2. Product Portfolio
16.3.8.3. Financial Overview
16.3.8.4. SWOT Analysis
16.3.8.5. Strategic Overview
16.3.9. Illumina, Inc.
16.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
16.3.9.2. Product Portfolio
16.3.9.3. Financial Overview
16.3.9.4. SWOT Analysis
16.3.9.5. Strategic Overview

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings